HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shields, A. F. Articles by Krohn, K. A. Search for Related Content PubMed PubMed Citation Articles by Shields, A. F. Articles by Krohn, K. A.

Utilization of Labeled Thymidine in DNA Synthesis: Studies for PET

Departments of Medicine and Radiology (Nuclear Medicine), University of Washington, Seattle
VA Medical Center
Fred Hutchinson Cancer Research Center, Seattle, Washington

Correspondence: For reprints contact: Dr. Anthony Shields, Seattle VA Medical Center, Mail Stop (111), 1660 S. Columbian Way, Seattle, WA 98108.

ABSTRACT

Carbon-111-thymidine and positron emission tomography (PET)have the potential for noninvasively measuring DNA synthesis in tumors and tissues. In order to validate this potential, one needs to construct accurate biochemical models that reflect the metabolism of thymidine, including its uptake and degradation as well as its incorporation into DNA. Our studies employed thymidine labeled in the methyl position using ¹¹C, ¹⁴C, and ³H. Studies with rapidly proliferating tissues of mice demonstrated that most of the activity, 60 min after injection of labeled thymidine, was present in DNA, with smaller amounts found in metabolites. Studies in dogs, however, reveal that more activity was present in metabolites, rather than in the DNA of tumors and spleen tissue. HPLC analysis of canine blood after the injection of thymidine revealed rapid conversion of thymidine to thymine and other metabolites. We have found significant differences in the metabolism of [³H]thymidine versus thymidine labeled with radioactive carbon. These differences, which were not found when comparing ¹⁴C and ¹¹C, indicate that [³H]thymidine is not an appropriate standard for comparison with PET studies employing [¹¹C] thymidine. To accurately interpret images of [¹¹C]thymidine as representations of DNA synthesis we are developing kinetic models that take into account the metabolism of thymidine and the contribution of degradation products to the ¹¹C images.

This article has been cited by other articles:

				A. van Waarde, L. B. Been, K. Ishiwata, R. A. Dierckx, and P. H. Elsinga Early Response of {sigma}-Receptor Ligands and Metabolic PET Tracers to 3 Forms of Chemotherapy: An In Vitro Study in Glioma Cells J. Nucl. Med., September 1, 2006; 47(9): 1538 - 1545. [Abstract] [Full Text] [PDF]

				S. Nimmagadda, T. J. Mangner, H. Sun, R. W. Klecker Jr., O. Muzik, J. M. Lawhorn-Crews, K. A. Douglas, J. M. Collins, and A. F. Shields Biodistribution and Radiation Dosimetry Estimates of 1-(2'-Deoxy-2'-18F-Fluoro-1-{beta}-D-Arabinofuranosyl)-5-Bromouracil: PET Imaging Studies in Dogs J. Nucl. Med., November 1, 2005; 46(11): 1916 - 1922. [Abstract] [Full Text] [PDF]

				P. Wells, R. N. Gunn, C. Steel, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price 2-[11C]Thymidine Positron Emission Tomography Reproducibility in Humans Clin. Cancer Res., June 15, 2005; 11(12): 4341 - 4347. [Abstract] [Full Text] [PDF]

				H. Sun, T. J. Mangner, J. M. Collins, O. Muzik, K. Douglas, and A. F. Shields Imaging DNA Synthesis In Vivo with 18F-FMAU and PET J. Nucl. Med., February 1, 2005; 46(2): 292 - 296. [Abstract] [Full Text] [PDF]

				L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]

				L. Lu, L. Samuelsson, M. Bergstrom, K. Sato, K.-J. Fasth, and B. Langstrom Rat Studies Comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as Proliferation Markers J. Nucl. Med., December 1, 2002; 43(12): 1688 - 1698. [Abstract] [Full Text] [PDF]

				P. Wells, R. N. Gunn, M. Alison, C. Steel, M. Golding, A. S. Ranicar, F. Brady, S. Osman, T. Jones, and P. Price Assessment of Proliferation in Vivo Using 2-[11C]Thymidine Positron Emission Tomography in Advanced Intra-abdominal Malignancies Cancer Res., October 15, 2002; 62(20): 5698 - 5702. [Abstract] [Full Text] [PDF]

				L. Lu, M. Bergstrom, K.-J. Fasth, and B. Langstrom Synthesis of [76Br]Bromofluorodeoxyuridine and Its Validation with Regard to Uptake, DNA Incorporation, and Excretion Modulation in Rats J. Nucl. Med., October 1, 2000; 41(10): 1746 - 1752. [Abstract] [Full Text] [PDF]

				R. G. Blasberg, U. Roelcke, R. Weinreich, B. Beattie, K. von Ammon, Y. Yonekawa, H. Landolt, I. Guenther, N. E. A. Crompton, P. Vontobel, et al. Imaging Brain Tumor Proliferative Activity with [124I]Iododeoxyuridine Cancer Res., February 1, 2000; 60(3): 624 - 635. [Abstract] [Full Text]

				J. F. Eary, D. A. Mankoff, A. M. Spence, M. S. Berger, A. Olshen, J. M. Link, F. O'Sullivan, and K. A. Krohn 2-[C-11]Thymidine Imaging of Malignant Brain Tumors Cancer Res., February 1, 1999; 59(3): 615 - 621. [Abstract] [Full Text] [PDF]